Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

azenta inc. - AZTA

AZTA

Close Chg Chg %
45.53 -0.37 -0.81%

Closed Market

45.16

-0.37 (0.81%)

Volume: 10.02M

Last Updated:

Nov 22, 2024, 4:00 PM EDT

Trade Now

Company Overview: azenta inc. - AZTA

AZTA Key Data

Open

$45.47

 Day Range

44.83 - 46.44

52 Week Range

38.82 - 69.16

 Market Cap

$2.23B

Shares Outstanding

48.92M

 Public Float

47.65M

Beta

1.48

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$2.97

Yield

0.00%

 Dividend

$0.10

EX-DIVIDEND DATE

Dec 2, 2021

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.08M

  

AZTA Performance

1 Week
 
 8.79%
 
1 Month
 
 10.50%
 
3 Months
 
 -8.29%
 
1 Year
 
 -21.68%
 
5 Years
 
 4.27%
 

AZTA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About azenta inc. - AZTA

Azenta, Inc. is a provider of life sciences sample exploration and management solutions for the life sciences market. It operates through the Life Sciences Products and Life Sciences Services segments. The Life Sciences Products segment is involved in automated cold storage solutions for biological and chemical compound samples. The Life Sciences Services segment focuses on the solutions addressing the many needs of customers in the area of genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development markets. The company was founded in 1978 and is headquartered in Burlington, MA.

AZTA At a Glance

Azenta, Inc.
200 Summit Drive
Burlington, Massachusetts 01803
Phone 1-978-262-2400 Revenue 656.32M
Industry Medical/Nursing Services Net Income -164,170,000.00
Sector Health Services Employees N/A
Fiscal Year-end 09 / 2025
View SEC Filings

AZTA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 3.925
Price to Book Ratio 1.248
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 136.72
Enterprise Value to Sales 3.307
Total Debt to Enterprise Value 0.027

AZTA Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover 3.80
Total Asset Turnover 0.263

AZTA Liquidity

Current Ratio 4.066
Quick Ratio 3.503
Cash Ratio 2.266

AZTA Profitability

Gross Margin 40.128
Operating Margin -11.107
Pretax Margin -25.494
Net Margin -25.014
Return on Assets -6.586
Return on Equity -7.63
Return on Total Capital -8.982
Return on Invested Capital -7.422

AZTA Capital Structure

Total Debt to Total Equity 3.324
Total Debt to Total Capital 3.217
Total Debt to Total Assets 2.80
Long-Term Debt to Equity 3.324
Long-Term Debt to Total Capital 3.217
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Azenta Inc. - AZTA

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
513.70M 555.50M 665.07M 656.32M
Sales Growth
-42.75% +8.14% +19.73% -1.32%
Cost of Goods Sold (COGS) incl D&A
299.19M 324.88M 431.82M 392.96M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
56.87M 53.70M 85.58M 88.77M
Depreciation
19.50M 21.41M 37.21M 37.50M
Amortization of Intangibles
37.37M 32.29M 48.38M 51.27M
COGS Growth
-45.37% +8.59% +32.92% -9.00%
Gross Income
214.51M 230.62M 233.26M 263.37M
Gross Income Growth
-38.63% +7.51% +1.14% +12.91%
Gross Profit Margin
+41.76% +41.52% +35.07% +40.13%
2021 2022 2023 2024 5-year trend
SG&A Expense
210.91M 254.64M 315.45M 336.26M
Research & Development
22.41M 27.54M 33.96M 33.52M
Other SG&A
188.50M 227.10M 281.50M 302.74M
SGA Growth
-19.20% +20.73% +23.88% +6.60%
Other Operating Expense
- - - -
-
Unusual Expense
34.69M 1.34M (9.07M) 127.78M
EBIT after Unusual Expense
(31.09M) (25.37M) (73.13M) (200.68M)
Non Operating Income/Expense
(15.84M) 20.02M 42.69M 33.35M
Non-Operating Interest Income
632.00K 20.29M 43.73M 33.18M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 2.04M 4.59M
-
Interest Expense Growth
- - -30.81% +125.28%
-
Gross Interest Expense
- - 2.04M 4.59M
-
Interest Capitalized
- - - -
-
Pretax Income
(48.97M) (9.94M) (30.43M) (167.32M)
Pretax Income Growth
-165.32% +79.71% -206.29% -449.81%
Pretax Margin
-9.53% -1.79% -4.58% -25.49%
Income Tax
(20.10M) 1.35M (17.55M) (3.15M)
Income Tax - Current - Domestic
- (15.11M) (4.22M) 929.00K
Income Tax - Current - Foreign
- 15.48M 4.63M 9.76M
Income Tax - Deferred - Domestic
- (13.75M) (995.00K) (19.09M)
Income Tax - Deferred - Foreign
- (6.72M) 1.94M (9.15M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(28.87M) (11.29M) (12.88M) (164.17M)
Minority Interest Expense
- - - -
-
Net Income
(28.87M) (11.29M) (12.88M) (164.17M)
Net Income Growth
-144.39% +60.91% -14.15% -1,174.31%
Net Margin Growth
-5.62% -2.03% -1.94% -25.01%
Extraordinaries & Discontinued Operations
- 139.62M (417.68M) (1.37M)
Discontinued Operations
- 139.62M (417.68M) (1.37M)
Net Income After Extraordinaries
110.75M (428.96M) (14.26M) (164.17M)
Preferred Dividends
- - - -
-
Net Income Available to Common
110.75M (428.96M) (14.26M) (164.17M)
EPS (Basic)
1.492 -5.7274 -0.2152 -3.0873
EPS (Basic) Growth
+69.22% -483.87% +96.24% -1,334.62%
Basic Shares Outstanding
74.23M 74.90M 66.25M 53.17M
EPS (Diluted)
1.4874 -5.7274 -0.2152 -3.0873
EPS (Diluted) Growth
+69.37% -485.06% +96.24% -1,334.62%
Diluted Shares Outstanding
74.45M 74.90M 66.25M 53.17M
EBITDA
60.47M 29.68M 3.39M 15.88M
EBITDA Growth
-60.74% -50.92% -88.59% +368.84%
EBITDA Margin
+11.77% +5.34% +0.51% +2.42%

Snapshot

Average Recommendation HOLD Average Target Price 49.40
Number of Ratings 7 Current Quarters Estimate 0.048
FY Report Date 12 / 2024 Current Year's Estimate 0.385
Last Quarter’s Earnings 0.18 Median PE on CY Estimate N/A
Year Ago Earnings 0.41 Next Fiscal Year Estimate 0.678
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 6 6 6 6
Mean Estimate 0.05 0.05 0.39 0.68
High Estimates 0.08 0.09 0.43 0.81
Low Estimate 0.01 -0.02 0.32 0.44
Coefficient of Variance 60.56 102.08 11.23 20.54

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 5 5 5
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Hold Hold Hold

Insider Actions for Azenta Inc. - AZTA

Date Name Shares Transaction Value
Nov 8, 2024 Quentin George Koffey Director 995 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 23, 2024 Violetta A. Hughes VP, Chief Accounting Officer 3,162 Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 Non-derivative transaction at $51.36 per share 162,400.32
Mar 12, 2024 Jason W. Joseph SVP, General Counsel, Secy. 106,006 Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 Non-derivative transaction at $65.21 per share 6,912,651.26
Mar 12, 2024 Jason W. Joseph SVP, General Counsel, Secy. 102,006 Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 Non-derivative transaction at $65.2 per share 6,650,791.20
Mar 12, 2024 Jason W. Joseph SVP, General Counsel, Secy. 98,006 Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 Non-derivative transaction at $65 per share 6,370,390.00
Mar 12, 2024 Jason W. Joseph SVP, General Counsel, Secy. 94,006 Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 Non-derivative transaction at $67.5 per share 6,345,405.00
Feb 14, 2024 Martin D. Madaus Director 2,465 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $65.93 per share 162,517.45
Feb 14, 2024 Edward Peter Bousa Director 2,465 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $65.93 per share 162,517.45
Feb 14, 2024 Didier Hirsch Director 2,465 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $65.93 per share 162,517.45
Feb 14, 2024 Michael A. Rosenblatt Director 13,042 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $65.93 per share 859,859.06
Feb 14, 2024 Robyn C. Davis Director 29,587 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $65.93 per share 1,950,670.91
Feb 14, 2024 Tina Susan Nova Director 6,069 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $65.93 per share 400,129.17
Feb 14, 2024 Erica J. McLaughlin Director 12,818 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $65.93 per share 845,090.74
Feb 14, 2024 Frank E. Casal Director 9,392 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $65.93 per share 619,214.56
Dec 7, 2023 Robin Vacha SVP, GM Life Science Products 25,788 Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 Non-derivative transaction at $56.6 per share 1,459,600.80

Azenta Inc. in the News